

CLAIMS

What is claimed is:

1. Use of a pharmaceutical composition comprising:

at least one purified viral L1 protein, wherein the at least one purified viral L1 is a quadrivalent human papilloma virus (HPV) L1 protein or fragment thereof comprising HPV types 6,11,16, and 18 or a multivalent human papilloma virus (HPV) L1 protein or fragment thereof comprising HPV types 16, 18, 31, 33, 45, 52 and 58 and is free of host-cell and/or non-L1 HPV peptide,

a second active pharmaceutical ingredient wherein the second active pharmaceutical ingredient is a local anesthetic, and the local anesthetic is lidocaine; and

a pharmaceutically-acceptable carrier,

in the manufacture of a medicament for the treatment of skin cancer, cancerous tumor, or a human papilloma virus (HPV)-associated cancerous lesion, wherein the medicament is to be administered by injection to a subject.
2. The use of claim 1, wherein each dose of the composition is 0.5 ml.
3. The use of claim 1, wherein the at least one purified viral L1 protein is present in a virus-like particle (VLP).
4. The use of any one of claims 1 to 3, wherein the at least one purified viral L1 protein and the second active pharmaceutical ingredient and pharmaceutically acceptable carrier are in a unitary dosage form.